A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.

Abstract

Sorry, we couldn't extract an abstract for this paper.
DOI: 10.3109/10428194.2016.1138295

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics